Kymera Therapeutics, Inc.’s KYMR share price has surged by 11.54%, which has investors questioning if this is right time to sell.

Women with the autoimmune diseases rheumatoid arthritis, lupus or systemic sclerosis may have a higher rate of death related ...

The chronic pruritus market is expected to grow across the 7MM, driven by the introduction of innovative therapies like ...

In a new study, researchers have identified a way to stop cells from dying, opening the door to developing treatments that ...

The intestinal immune system is vital for maintaining mucosal homeostasis and mediating interactions between the host and its ...